Physician

Thomas A. Moore, MD

According to 2025 Medicare claims, Thomas Moore, MD (NPI: 1407851181) practices infectious disease in the Wichita, KS market, with the plurality of this provider's patient population coming from Sedgwick, KS. This provider's primary affiliated billing organization is INFECTIOUS DISEASE CONSULTANTS, P.A. (NPI: 1306830641; TIN: 480894464) and primary practice location at 67211-2129. Moore is affiliated with the Aledade 38 KS CHC MSSP Enhanced (ACO ID: A4546) and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Moore's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 843 traditional Medicare patients, billed 215,649 HCPCS/CPT codes, and received $990,004 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 577 prescription claims across 186 beneficiaries totaling $160,247 in drug costs, led by Daptomycin (Daptomycin). Open Payments data shows 32 records totaling $34,400. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $302,108 to $990,004. In contrast, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $220,664 to $160,247. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	804	5,164	$302,108
2016	781	25,689	$330,681
2017	818	26,071	$361,872
2018	912	87,915	$440,455
2019	932	99,332	$432,893
2020	904	148,582	$558,460
2021	826	237,103	$566,700
2022	771	218,583	$739,921
2023	810	159,101	$817,867
2024	843	215,649	$990,004

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	102	340	$220,664
2016	91	346	$497,670
2017	97	362	$62,629
2018	115	414	$430,286
2019	121	457	$208,139
2020	115	460	$234,519
2021	134	506	$178,408
2022	144	487	$121,172
2023	127	368	$161,600
2024	186	577	$160,247

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	198	213	$128
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	230	252	$96
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	256	940	$88
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	459	1,818	$58
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	180	745	$44

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Daptomycin	Daptomycin	37	251	$31,448
Ertapenem	Ertapenem Sodium	13	92	$6,443
Ceftriaxone	Ceftriaxone Sodium	15	107	$3,572
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	12	420	$3,505
Cefdinir	Cefdinir	38	1,039	$2,726

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	32	$34,400	AIMMUNE THERAPEUTICS, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Thomas A. Moore, MD?

Tedicare shows public-source Medicare data for Thomas A. Moore, MD (NPI 1407851181), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas A. Moore, MD have ACO affiliation data?

Thomas A. Moore, MD is shown with ACO affiliation data for Aledade 38 KS CHC MSSP Enhanced (MSSP, ACO ID A4546) and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Thomas A. Moore, MD?

Thomas A. Moore, MD is linked to INFECTIOUS DISEASE CONSULTANTS, P.A. (billing NPI 1306830641) in the available physician profile data.

Does Thomas A. Moore, MD have Open Payments data?

Thomas A. Moore, MD has 32 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.